Phosphodiesterase 4 cAMP phosphodiesterases as targets for novel anti-inflammatory therapeutics

Allergology International

Volumn 53, Issue 2, 2004, Pages 101-110

  MacKenzie, Simon J ^a  

^a Scottish Biomedical   (United Kingdom)

Author keywords

A kinase anchoring protein (AKAP); Phosphodiesterase 4; Phosphodiesterase inhibitors; Src tyrosine kinase; arrestin

Indexed keywords

4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; ANTIINFLAMMATORY AGENT; CYCLIC AMP; CYCLIC NUCLEOTIDE; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR;

CANCER; CELLULAR DISTRIBUTION; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; HUMAN; INFLAMMATION; KNOCKOUT MOUSE; MOUSE; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; VIRUS INFECTION; VOMITING;

EID: 3142554188     PISSN: 13238930     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1323-8930.2004.00318.x     Document Type: Review

References (43)

1. Moore AR, Willoughby DA. The role of cAMP regulation in controlling inflammation. Clin. Exp. Immunol. 1995; 101: 387-9.
2. Spina D. Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease. Drugs 2003; 63: 2575-94.
3. Barnes PJ. Chronic obstructive pulmonary disease * 12: New treatments for COPD. Thorax 2003; 58: 803-8.
4. Holtzman MJ. Drug development for asthma. Am. J. Respir. Cell. Mol. Biol. 2003; 29: 163-71.
5. Dyke HJ, Montana JG. Update on the therapeutic potential of PDE4 inhibitors. Expert Opin. Invest. Drugs 2002; 11: 1-13.
6. Houslay MD, Adams DR. PDE4 cAMP phosphodiesterases: Modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem. J. 2003; 370: 1-18.
7. Jin SL, Conti M. Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses. Proc. Natl Acad. Sci. USA 2002; 99: 7628-33.
8. Hansen G, Jin S, Umetsu DT, Conti M. Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D. Proc. Natl Acad. Sci. USA 2000; 97: 6751-6.
9. Soderling SH, Beavo JA. Regulation of cAMP and cGMP signaling: New phosphodiesterases and new functions. Curr. Opin. Cell Biol. 2000; 12: 174-9.
10. Conti M, Jin SL. The molecular biology of cyclic nucleotide phosphodiesterases. Prog. Nucleic Acids Res. Mol. Biol. 1999; 63: 1-38.
11. Beard MB, Olsen AE, Jones RE, Erdogan S, Houslay MD, Bolger GB. UCR1 and UCR2 domains unique to the cAMP-specific phosphodiesterase family form a discrete module via electrostatic interactions. J. Biol. Chem. 2000; 275: 10 349-58.
12. Burnouf C, Pruniaux MP. Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs. Curr. Pharm. Des. 2002; 8: 1255-96.
13. Huang Z, Ducharme Y, Macdonald D, Robichaud A. The next generation of PDE4 inhibitors. Curr. Opin. Chem. Biol. 2001; 5: 432-8.
14. Giembycz MA. Development status of second generation PDE4 inhibitors for asthma and COPD: The story so far. Monaldi Arch. Chest Dis. 2002; 57: 48-64.
15. Robichaud A, Savoie C, Stamatiou PB et al. Assessing the emetic potential of PDE4 inhibitors in rats. Br. J. Pharmacol. 2002; 135: 113-18.
16. Robichaud A, Stamatiou PB, Jin SL et al. Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J. Clin. Invest. 2002; 110: 1045-52.
17. Mehats C, Jin SL, Wahlstrom J, Law E, Umetsu DT, Conti M. PDF4D plays a critical role in the control of airway smooth muscle contraction. FASEB J. 2003; 17: 1831-41.
18. Richter W, Unciuleac L, Hermsdorf T, Kronbach T, Dettmer D. Identification of inhibitor binding sites of the cAMP-specific phosphodiesterase 4. Cell Signal. 2001; 13: 287-97.
19. Rich TC, Fagan KA, Tse TE, Schaack J, Cooper DM, Karpen JW. A uniform extracellular stimulus triggers distinct cAMP signals in different compartments of a simple cell. Proc. Natl Acad. Sci. USA 2001; 98: 13 049-54.
20. MacKenzie SJ, Baillie GS, McPhee I et al. Long PDE4 cAMP specific phosphodiesterases are activated by protein kinase A-mediated phosphorylation of a single serine residue in Upstream Conserved Region 1 (UCR1). Br. J. Pharmacol. 2002; 136: 421-33.
21. Hoffmann R, Wilkinson R, McCallum JF, Engels P, Houslay MD. cAMP-specific phosphodiesterase HSPDE4D3 mutants which mimic activation and changes in rolipram inhibition triggered by protein kinase A phosphorylation of Ser-54: Generation of a molecular model. Biochem. J. 1998; 333: 139-49.
22. Oki N, Takahashi SI, Hidaka H, Conti M. Short term feedback regulation of cAMP in FRTL-5 thyroid cells. Role of PDE4D3 phosphodiesterase activation. J. Biol. Chem. 2000; 275: 10 831-7.
23. Hoffmann R, Baillie GS, MacKenzie SJ, Yarwood SJ, Houslay MD. The MAP kinase ERK2 inhibits the cyclic AMP-specific phosphodiesterase HSPDE4D3 by phosphorylating it at Ser579. EMBO J. 1999; 18: 893-903.
24. Baillie GS, MacKenzie SJ, McPhee I, Houslay MD. Sub-family selective actions in the ability of Erk2 MAP kinase to phosphorylate and regulate the activity of PDE4 cyclic AMP-specific phosphodiesterases. Br. J. Pharmacol. 2000; 131: 811-19.
25. MacKenzie SJ, Houslay MD. Action of rolipram on specific PDE4 cAMP phosphodiesterase isoforms and on the phosphorylation of cAMP-response-element- binding protein (CREB) and p38 mitogen-activated protein (MAP) kinase in U937 monocytic cells. Biochem. J. 2000; 347: 571-8.
26. Beard MB, Huston E, Campbell L et al. In addition to the SH3 binding region, multiple regions within the N-terminal noncatalytic portion of the cAMP-specific phosphodiesterase, PDE4A5, contribute to its intracellular targeting. Cell Signal. 2002; 14: 453-65.
27. McPhee I, Yarwood SJ, Scotland G et al. Association with the SRC family tyrosyl kinase LYN triggers a conformational change in the catalytic region of human cAMP-specific phosphodiesterase HSPDE4A4B. Consequences for rolipram inhibition. J. Biol. Chem. 1999; 274: 11 796-810.
28. Beard MB, O'Connell JC, Bolger GB, Houslay MD. The unique N-terminal domain of the cAMP phosphodiesterase PDE4D4 allows for interaction with specific SH3 domains. FEBS Lett. 1999; 460: 173-7.
29. Abrahamsen H, Vang T, Tasken K. Protein kinase A intersects SRC signaling in membrane microdomains. J. Biol. Chem. 2003; 278: 17 170-7.
30. Yaqub S, Abrahamsen H, Zimmerman B et al. Activation of C-terminal Src kinase (Csk) by phosphorylation at serine-364 depends on the Csk-Src homology 3 domain. Biochem. J. 2003; 372: 271-8.
31. Huston E, Beard M, McCallum F et al. The cAMP-specific phosphodiesterase PDE4A5 is cleaved downstream of its SH3 interaction domain by caspase-3. Consequences for altered intracellular distribution. J. Biol. Chem. 2000; 275: 28 063-74.
32. Dodge KL, Khouangsathiene S, Kapiloff MS et al. mAKAP assembles a protein kinase A/PDE4 phosphodiesterase cAMP signaling module. EMBO J. 2001; 20: 1921-30.
33. Tasken KA, Collas P, Kemmer WA, Witczak O, Conti M, Tasken K. Phosphodiesterase 4D and protein kinase a type II constitute a signaling unit in the centrosomal area. J. Biol. Chem. 2001; 276: 21 999-2002.
34. Hallsworth MP, Twort CH, Lee TH, Hirst SJ. Beta(2)-adrenaceptor agonists inhibit release of eosinophil-activating cytakines from human airway smooth muscle cells. Br. J. Pharmacol. 2001; 132: 729-41.
35. Pang L, Knox AJ. Synergistic inhibition by beta (2)-agonists and corticosteroids on tumor necrosis factar-alpha-induced interleukin-8 release from cultured human airway smooth-muscle cells. Am. J. Respir. Cell. Mal. Biol. 2000; 23: 79-85.
36. Rabe KF. State of the art in beta2-agonist therapy: A safety review of long-acting agents. Int. J. Clin. Pract. 2003; 57: 689-97.
37. Rousell J, Haddad EB, Mak JC, Webb BL, Giembycz MA, Barnes PJ. beta-Adrenoceptor-medicated down-regulation of M2 muscarinic receptors: Role of cyclic adenosine 5′-monophosphate-dependent protein kinase and protein kinase C. Mol. Pharmacol. 1996; 49: 629-35.
38. i. Proc. Natl Acad. Sci. USA 2003; 100: 940-5.
39. Perry SJ, Baillie GS, Kohout TA et al. Targeting of cyclic AMP degradation to beta 2-adrenergic receptors by beta-arrestins. Science 2002; 298: 834-6.
40. Bolger GB, McCahill A, Huston E et al. The unique amino-terminal region of the PDE4D5 cAMP phosphodiesterase isoform confers preferential interaction with beta-arrestins. J. Biol. Chem. 2003; 278: 49 230-8.
41. MacKenzie SJ, Baillie GS, McPhee I, Bolger GB, Houslay MD. ERK2 mitogen-activated protein kinase binding, phosphorylation, and regulation of the PDE4D cAMP-specific phosphodiesterases. The involvement of COOH-terminal docking sites and NH2-terminal UCR regions. J. Biol. Chem. 2000; 275: 16 609-17.
42. Yarwood SJ, Steele MR, Scotland G, Houslay MD, Bolger GB. The RACK1 signaling scaffold protein selectively interacts with the cAMP-specific phosphodiesterase PDE4D5 isoform. J. Biol. Chem. 1999; 274: 14 909-17.
43. Bolger GB, McCahill A, Yarwood SJ, Steele MS, Worwicker J, Houslay MD. Delineation of RAID1, the RACK1 interaction domain located within the unique N-terminal region of the cAMP-specific phosphodiesterase, PDE4D5. BMC Biochem. 2002; 3: 24.